KemPharm Completes its Initial Public Offering

Colorado – April 28, 2015 – Cooley advised KemPharm, Inc. on its initial public offering.  KemPharm, based in Coralville, Iowa, is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that it believes will be improved versions of widely prescribed, approved drugs. The company trades on The NASDAQ Global Market under the symbol "KMPH."

The Cooley corporate securities team advising KemPharm was comprised of partners Jim Linfield, Brent Siler and Matt Dubofsky and associates Mark Ballantyne, Nathan Jeffries and Bin Wang.

Critical support for the offering was provided by partner Natasha Leskovsek and special counsel Phil Mitchell (health care and life sciences regulatory); partner Thomas Welk (compensation and benefits); and partner Susan Cooper Philpot and senior counsel Bill Morrow (tax).

About Cooley LLP

Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Susan Cooper Philpot Retired Partner San Francisco
Bill Morrow Retired Partner San Diego
James Linfield Senior Counsel Colorado
Thomas Welk Senior Counsel San Diego
Matthew Dubofsky Partner Colorado
Brent Siler Partner Washington, DC, Reston
Natasha Leskovsek Of Counsel Washington, DC
Mark Ballantyne Associate Reston
Phil Mitchell Partner New York